{"id":"https://openalex.org/W2397960759","doi":"https://doi.org/10.1016/j.jval.2016.03.1539","title":"Uptake of TBO-Filgrastim in the Outpatient Setting among Commercially Insured and Medicare Supplemental Populations in the United States","display_name":"Uptake of TBO-Filgrastim in the Outpatient Setting among Commercially Insured and Medicare Supplemental Populations in the United States","publication_year":2016,"publication_date":"2016-05-01","ids":{"openalex":"https://openalex.org/W2397960759","doi":"https://doi.org/10.1016/j.jval.2016.03.1539","mag":"2397960759"},"language":"en","primary_location":{"id":"doi:10.1016/j.jval.2016.03.1539","doi":"https://doi.org/10.1016/j.jval.2016.03.1539","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2016.03.1539","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301516016077/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"http://www.valueinhealthjournal.com/article/S1098301516016077/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089942904","display_name":"KE Smoyer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"KE Smoyer","raw_affiliation_strings":["Envision Pharma Group, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Envision Pharma Group, Philadelphia, PA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109380501","display_name":"CA Jones","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"CA Jones","raw_affiliation_strings":["Envision Pharma Group, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Envision Pharma Group, London, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112133337","display_name":"BH Johnson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189504160","display_name":"Truven Health Analytics (United States)","ror":"https://ror.org/00sf52z42","country_code":"US","type":"company","lineage":["https://openalex.org/I189504160"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"BH Johnson","raw_affiliation_strings":["Truven Health Analytics, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Truven Health Analytics, Cambridge, MA, USA","institution_ids":["https://openalex.org/I189504160"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000606742","display_name":"PB Lane","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"PB Lane","raw_affiliation_strings":["Envision Pharma Group, Horsham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Envision Pharma Group, Horsham, UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":null,"fwci":0.1701,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.57094843,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"19","issue":"3","first_page":"A170","last_page":"A170"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12172","display_name":"Neutropenia and Cancer Infections","score":0.8169000148773193,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12172","display_name":"Neutropenia and Cancer Infections","score":0.8169000148773193,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.1340000033378601,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.02630000002682209,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/biosimilars","display_name":"biosimilars","score":0.7770000100135803},{"id":"https://openalex.org/keywords/granulocyte-colony-stimulating-factor","display_name":"granulocyte colony-stimulating factor","score":0.8610000014305115},{"id":"https://openalex.org/keywords/pegfilgrastim","display_name":"pegfilgrastim","score":0.8479999899864197},{"id":"https://openalex.org/keywords/filgrastim","display_name":"filgrastim","score":0.8560000061988831},{"id":"https://openalex.org/keywords/drug-uptake","display_name":"drug uptake","score":0.5979999899864197},{"id":"https://openalex.org/keywords/drug-utilization-patterns","display_name":"drug utilization patterns","score":0.5619999766349792},{"id":"https://openalex.org/keywords/commercially-insured-patients","display_name":"commercially insured patients","score":0.6629999876022339},{"id":"https://openalex.org/keywords/medicare-supplemental-insurance","display_name":"Medicare supplemental insurance","score":0.781000018119812},{"id":"https://openalex.org/keywords/chemotherapy-induced-neutropenia","display_name":"chemotherapy-induced neutropenia","score":0.8309999704360962},{"id":"https://openalex.org/keywords/cancer-patients","display_name":"cancer patients","score":0.718999981880188},{"id":"https://openalex.org/keywords/biosimilar-approval","display_name":"biosimilar approval","score":0.3089999854564667},{"id":"https://openalex.org/keywords/united-states-market-entry","display_name":"United States market entry","score":0.47699999809265137}],"concepts":[{"id":"https://openalex.org/C2779171977","wikidata":"https://www.wikidata.org/wiki/Q3151081","display_name":"Filgrastim","level":4,"score":0.9697086811065674},{"id":"https://openalex.org/C2778658803","wikidata":"https://www.wikidata.org/wiki/Q1592932","display_name":"Pegfilgrastim","level":5,"score":0.8580580353736877},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8204989433288574},{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.8067831993103027},{"id":"https://openalex.org/C2780084366","wikidata":"https://www.wikidata.org/wiki/Q37732","display_name":"Demographics","level":2,"score":0.5596799850463867},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5496838092803955},{"id":"https://openalex.org/C2777767877","wikidata":"https://www.wikidata.org/wiki/Q419327","display_name":"Granulocyte colony-stimulating factor","level":3,"score":0.5343341827392578},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44803497195243835},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.37528762221336365},{"id":"https://openalex.org/C149923435","wikidata":"https://www.wikidata.org/wiki/Q37732","display_name":"Demography","level":1,"score":0.2036181390285492},{"id":"https://openalex.org/C144024400","wikidata":"https://www.wikidata.org/wiki/Q21201","display_name":"Sociology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jval.2016.03.1539","doi":"https://doi.org/10.1016/j.jval.2016.03.1539","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2016.03.1539","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301516016077/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jval.2016.03.1539","doi":"https://doi.org/10.1016/j.jval.2016.03.1539","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2016.03.1539","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301516016077/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2542957667","https://openalex.org/W2770229835","https://openalex.org/W2398963676","https://openalex.org/W2603478346","https://openalex.org/W3128946849","https://openalex.org/W2810163667","https://openalex.org/W2255734180","https://openalex.org/W3215622274","https://openalex.org/W2950542048","https://openalex.org/W2891048555"],"abstract_inverted_index":null,"counts_by_year":[{"year":2018,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2016-06-24T00:00:00"}